Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Clinical characteristics and management of long survivors in extensive stage small cell lung cancer

作者:Élisa Gobbini, Mamadou Diallo, Dominique Pasquier, Sophie C. Schneider, C. Chouaïd, D. Debieuvre, Xavier Quantin, Radj Gervais, Clarisse Audigier-Valette, G. Justeau, Magali Ravoire, Anne Madroszyk, Éric Pichon, Lionel Falchero, Yannick Simoneau, Olivier Bylicki, A. Baranzelli, L. Bosquet, M. Pérol, Nicolas Girard · 发表于:Lung Cancer · 年份:2025 · 被引用次数:8 · 研究领域:Lung Cancer Research Studies、Lung Cancer Treatments and Mutations、Radiomics and Machine Learning in Medical Imaging

BACKGROUND: Extensive disease small cell lung cancer (ED-SCLC) accounts for more than 70% of new diagnoses of SCLC with a 5-year survival of 12%. A limited percentage of ED-SCLC achieved a long term survival but their clinical and biological characteristics are largely unknown. Here we reported baseline clinical characteristics and treatment sequences of a large cohort of Long Survivors ED-SCLC compared to patients with poor outcomes. METHODS: The Epidemio-Strategy and Medical Economics (ESME) lung cancer data platform is a multicenter real-life database using a retrospective data collection process. We selected ED-SCLC patients diagnosed between 2014 and 2021. Long Survivors were defined as having an overall survival (OS) ≥ 24 months. Statistical comparisons were performed by Pearson's Chi-square, and logistic regression. RESULTS: We identified 3150 ED-SCLC and 489 long survivors representing 13 % of the study population. mOS was 36 months (95 %CI 34 to 39) in Long Survivors and 9 months (95 %CI 8.9 to 9.4) in other patients. Compared to Short Survivors, Long Survivors were enriched in women, patients younger than 65 years-old, ECOG PS 0-1 at diagnosis less than 3 metastatic sites and never or former smokers. The C-statistic of the multiparametric model based on patient's clinical characteristics was estimated at 0.70, with a 95 % CI (0.68, 0.73). Among those patients receiving a platinum-based chemotherapy with or without immunotherapy in first-line, a prolonged survival be...